0001615774-18-006006.txt : 20180629 0001615774-18-006006.hdr.sgml : 20180629 20180629163040 ACCESSION NUMBER: 0001615774-18-006006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180628 FILED AS OF DATE: 20180629 DATE AS OF CHANGE: 20180629 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEDERMAN SETH CENTRAL INDEX KEY: 0001563420 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 18929636 MAIL ADDRESS: STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP STREET 2: 509 MADISON AVE., SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 1-800-849-7894 MAIL ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 4 1 s111120_form4.xml 4 X0306 4 2018-06-28 0 0001430306 Tonix Pharmaceuticals Holding Corp. TNXP 0001563420 LEDERMAN SETH C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK NY 10022 1 1 0 0 Chief Executive Officer Common Stock, $0.001 par value 2018-06-28 4 P 0 500 4.58 A 17166 D Common Stock, $0.001 par value 22700 I By 401(k) plan Common Stock, $0.001 par value 45900 I By IRA account Common Stock, $0.001 par value 3100 I By spouse Common Stock, $0.001 par value 2917 I By Leder Laboratories, Inc. Common Stock, $0.001 par value 2917 I By Starling Pharmaceuticals, Inc. Common Stock, $0.001 par value 20463 I By Lederman & Co., LLC Common Stock, $0.001 par value 3246 I By L&L Technologies, LLC Common Stock, $0.001 par value 5898 I By Targent Pharmaceuticals, LLC The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.57 to $4.59 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Reporting person may be deemed to be a control person of this entity. /s/ Seth Lederman 2018-06-29